Waters (WAT) Stock Forecast & Price Target

Waters is supported by an attractive replacement cycle in analytical instruments, with many aging flow cytometers and chromatography systems due for refresh, while higher-performance platforms like Xevo MRT, TQ Absolute XR, and Alliance iS should lift mix, pricing, and recurring reagent, service, and software revenue. Its positive outlook is further strengthened by the early 2026 BD life science and diagnostics merger, which roughly doubled the company and is expected to contribute about $200 million of cost savings and 170–200 bps of operating-margin expansion by 2027, alongside a stronger free-cash-flow profile. Waters is also benefiting from durable structural tailwinds in pharma manufacturing reshoring, GLP-1 workflows, and microbiology, where embedded installed bases, long contracts, and pricing opportunities can support resilient organic growth and earnings power.

Waters is facing a fundamentally weaker setup because the early 2026 merger with Becton Dickinson’s life science and diagnostics business adds operational complexity, roughly $4B of assumed debt, and a larger exposure to businesses that were already showing share loss and challenged growth trends. The company’s core analytical instruments franchise, while still a strength at about 15% of sales and helped by post-COVID and reshoring tailwinds, is not enough to offset the risk that integration hiccups, tougher comps, and market saturation slow organic growth and pressure margins. With a balance sheet now constrained and a ~16,000-person global workforce to manage, the risk is that management attention and capital allocation flexibility are diverted just as competitive pressure and underperforming acquired assets weigh on returns.